| Dactolisib studied in …STUDIED_INderived16 of 16show fewer |
|---|
| → studied in | NCT01756118Phase 1 · completed A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia · 16 trials list this drug (0 active) | — | — | Leukemia,Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00620594Phase 1 · completed A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer · 16 trials list this drug (0 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01195376Phase 1 · completed A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors · 16 trials list this drug (0 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01634061Phase 1 · completed Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients · 16 trials list this drug (0 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01495247Phase 1/Phase 2 · terminated Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer · 16 trials list this drug (0 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01856101Phase 2 · terminated Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based Chemotherapy · 16 trials list this drug (0 active) | — | — | Transitional Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01717898Phase 1/Phase 2 · terminated A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer · 16 trials list this drug (0 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01508104Phase 1 · terminated Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors · 16 trials list this drug (0 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01248494Phase 1 · completed PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer · 16 trials list this drug (0 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01658436Phase 2 · completed BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. · 16 trials list this drug (0 active) | — | — | Pancreatic Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01628913Phase 2 · terminated Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors · 16 trials list this drug (0 active) | — | — | Pancreatic Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01453595Phase 1/Phase 2 · terminated BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC) · 16 trials list this drug (0 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01343498Phase 1 · completed Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors · 16 trials list this drug (0 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01690871Phase 2 · withdrawn A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa · 16 trials list this drug (0 active) | — | — | Malignant PEComa | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01290406Phase 2 · withdrawn BEZ235 Trial in Patients With Advanced Endometrial Carcinoma · 16 trials list this drug (0 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01288092Phase 2 · withdrawn BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer · 16 trials list this drug (0 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |